Imagine 2026. The healthcare environment will be vastly different from today. New artificial intelligence (AI)-based technologies will reach surgical robots, medical devices, and even formulation design, completely reshaping the biohealth industry. At the heart of this technological revolution, South Korea is preparing to secure a significant position in next-generation medical fields, aligning with global trends. Let's explore the key areas, potential, and challenges of this transformation. AI surgical robots are already a central pillar of medical technology innovation. Surgical robot systems like Da Vinci are utilized in major medical institutions worldwide and are now evolving further through integration with AI technology. Government R&D projects are actively promoting the establishment and activation of an 'AI-powered Surgical Robot Innovation Lab'. This project is expected to serve as a core infrastructure to accelerate the commercialization of domestic AI surgical robot technology and secure global competitiveness. Particularly noteworthy is the convergence of 3D Vision technology and haptic feedback AI algorithms. 3D Vision technology enables AI to analyze surgical sites three-dimensionally, providing more precise visual information. This is used to understand complex anatomical structures in real-time and detect potential risks during surgery in advance. Haptic feedback technology takes this a step further. It's a technology that allows AI to transmit 'tactile information' to surgeons, enabling them to virtually feel the patient's tissue during surgery. Such advanced technology provides an environment akin to performing surgery right next to the patient, even for those located remotely. Retrospective analysis of robotic surgical data is also a crucial area of innovation. AI can analyze vast amounts of past surgical data to learn patterns and provide real-time surgical guidance. For example, AI can suggest incision paths or suturing methods with high success rates for specific types of surgery, supporting surgeons' decision-making. This data-driven approach is expected to significantly enhance surgical accuracy and safety. 5G-based ultra-low latency technology is making remote surgery a reality. When ultra-low latency 5G remote surgery networks are linked with AI surgical robots, specialists from large medical centers can perform remote surgeries in rural hospitals or areas with limited medical access. This will be a key to resolving regional disparities in healthcare services and providing personalized medical care to patients. For instance, a new treatment system where experts from around the world collaborate is expected to be established, and AI surgical robots will become an innovative tool that transcends the physical limitations of medicine. Meanwhile, trends in micro and nano surgical robot development are also gaining attention. This technology aims for precise in-body exploration and targeted drug delivery, presenting an entirely different approach from existing surgical robots. Micro-robots can penetrate deep into the body through blood vessels or narrow passages to directly explore lesion sites and, if necessary, deliver drugs to precise locations. Nano surgical robots are expected to operate on a much smaller scale, enabling cell-level precision treatment. Such technologies could offer innovative treatment options in various fields, including cancer treatment, cardiovascular diseases, and brain disorders. The commercialization of medical devices and integration with the insurance system are crucial factors for the successful establishment of digital healthcare. No matter how excellent innovative technology is, it is difficult to disseminate without commercial success. For AI-based diagnostic devices and machine learning models supporting personalized treatments to be commercialized in clinical settings, the medical device commercialization value chain and the insurance system must be organically linked. The AI medical device commercialization value chain encompasses the entire process from R&D to clinical trials, regulatory approval, manufacturing, distribution, and post-market management. A systematic approach is needed to understand how AI technology creates value at each stage and how to monetize it in the market. **Challenges in Medical Device Commercialization and Insurance System** In particular, developing insurance reimbursement models is a key challenge. The current insurance reimbursement system is designed around traditional medical services, so it requires significant time and effort for AI-based medical devices or services to be included as covered items. The process must involve proving the clinical efficacy and cost-effectiveness of new technologies and then determining appropriate reimbursement rates based on this evidence. This necessitates close cooperation among government, medical institutions, insurance companies, and technology developers. South Korea is one of th
Related Articles